|
|
Volumn 10, Issue 7, 2011, Pages 479-480
|
|
Excitement mounts for first disease-modifying cystic fibrosis drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AEROQUIN;
ANTIBIOTIC AGENT;
ANTIINFLAMMATORY AGENT;
ARIKACE;
ATALUREN;
GSK 656933;
ION TRANSPORT AFFECTING AGENT;
IVACAFTOR;
KB 001;
LUMACAFTOR;
MANNITOL;
TOBRAMYCIN;
TRANSMEMBRANE CONDUCTANCE REGULATOR;
UNCLASSIFIED DRUG;
VR 496;
VX 661;
VX 809;
ARTICLE;
CYSTIC FIBROSIS;
DISEASE EXACERBATION;
DRUG DESIGN;
DRUG EFFICACY;
DRUG RESEARCH;
GENE DELETION;
GENE DOSAGE;
GENE MUTATION;
GENE TARGETING;
HUMAN;
ION TRANSPORT;
LUNG FUNCTION;
NONSENSE MUTATION;
PRIORITY JOURNAL;
PROTEIN FOLDING;
PROTEIN TRANSPORT;
REGULATOR GENE;
TRANSMEMBRANE CONDUCTANCE REGULATOR GENE;
WEIGHT GAIN;
AMINOPHENOLS;
CLINICAL TRIALS AS TOPIC;
CYSTIC FIBROSIS;
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;
DRUG APPROVAL;
DRUG DISCOVERY;
HUMANS;
MUTATION;
QUINOLONES;
|
|
EID: 79960026348
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3488 Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|
